CMR Surgical Reveals Surgical Robot Milestone, Prepares to Enter U.S. Market

CMR Surgical revealed that over 45,000 patients across the world have been treated using the Versius surgical robotic system. This marks a milestone for the UK-based company as it prepares to expand into the U.S.

The company announced this achievement at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2026 annual meeting. CMR is rolling out Versius in the U.S. after U.S. Food and Drug Administration (FDA) clearance of the next-gen Versius Plus system in December 2025 for cholecystectomy.

CMR said the conference marks its formal introduction to U.S. surgeons, as it starts creating partnerships with hospitals and ambulatory surgery centers (ASCs) ahead of a broader rollout.

“This milestone is twofold and reflects the growing global momentum behind Versius and the confidence surgeons have in the platform,” said Massimiliano Colella, CEO of CMR Surgical. “But equally important, it comes at a watershed moment for CMR as we introduce Versius Plus to the U.S. surgical community and begin expanding access to our technology in the world’s largest robotic surgery market.”

Versius has been adopted in hospitals in over 30 countries and supports general surgery, colorectal surgery, urology, gynecology, and thoracic surgery.

“This is a pivotal moment for CMR,” said Chris O’Hara, president and general manager, U.S. “Versius Plus was designed to meet the practical realities of today’s healthcare environment; adaptable across operating rooms, efficient to integrate into existing surgical programs, and scalable for long-term growth. With FDA clearance now in place and additional indications planned, we are focused on partnering with forward-thinking health systems to expand the role of robotic-assisted surgery across specialties and care settings.”

The surgical robot features a modular design with independent robotic arms that can be positioned around the patient and efficiently moved between operating rooms.

“In surgical robotics, what ultimately matters is how a system performs in real clinical environments over time,” said Dr. Francesco Bianco, Division of General, Minimally Invasive & Robotic Surgery, University of Illinois Chicago. “What’s notable here is the scale of experience behind Versius, with tens of thousands of procedures contributing to a growing body of clinical understanding. That level of real-world use, and the data that come with it, is important as surgeons evaluate new technologies entering the U.S. market.”

In January, Versius received CE and UKCA marks in pediatric surgery, marking the company’s first regulatory nod for treating children. The approval was earned for abdominal surgery in children and infants under 18 years old.